| 0.8932 0.034 (3.91%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.3 | 1-year : | 1.5 |
| Resists | First : | 1.11 | Second : | 1.28 |
| Pivot price | 0.94  |
|||
| Supports | First : | 0.82 | Second : | 0.69 |
| MAs | MA(5) : | 0.87 |
MA(20) : | 0.95 |
| MA(100) : | 1.19 |
MA(250) : | 6.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10 |
D(3) : | 9.6 |
| RSI | RSI(14): 41.3 |
|||
| 52-week | High : | 99.75 | Low : | 0.82 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SDEV ] has closed above bottom band by 36.4%. Bollinger Bands are 17.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.92 - 0.92 | 0.92 - 0.93 |
| Low: | 0.86 - 0.86 | 0.86 - 0.87 |
| Close: | 0.88 - 0.89 | 0.89 - 0.9 |
Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.
Mon, 03 Aug 2026
SDEV: Abbott Cooper PLLC Announces Investigation on Behalf - GlobeNewswire
Fri, 03 Apr 2026
SDEV Stock Price and Chart — AMEX:SDEV - TradingView
Fri, 03 Apr 2026
Drugmaker NovaBay pivots to ‘Stablecoin Development Corporation’…accumulates 1.1 billion SKY tokens - bloomingbit
Thu, 02 Apr 2026
NovaBay Pharmaceuticals, Inc. will Change its Ticker to SDEV from NBY - marketscreener.com
Mon, 30 Mar 2026
NovaBay Pharmaceuticals Announces Corporate Name Change to Stablecoin Development Corporation - VisionMonday.com
Mon, 23 Mar 2026
Pharmaceutical stock surges 26% after crypto pivot - thestreet.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|